NanoViricides Inc. (NNVC)

[changes_iv]

“‘I think that it is entirely reasonable to assume that 30 million people would take a treatment for a dangerous flu that would end symptoms in just an hour or two — every year. Insurance companies would pay for the vast majority of uses.

“‘So $100 times 30 million uses is $3 billion a year,’ Patrick writes. ‘Double that for the European market and double it again for the world and you have potential sales easily exceeding $10 billion annually.

“‘Remember, this is an extremely inexpensive drug to manufacture when scaled up, so most of that revenue would fall into the profits column. When a pandemic hits, you would double sales… at least.

“‘The reason I say ‘at least’ is that an orally deliverable drug would work for flu prophylaxis, or prevention,’ Patrick continues. ‘Remember, this drug consists of big molecules compared with small molecule proteins. They are not metabolized and persist in the blood system for an extremely long time, perhaps months.

“‘This means that many people who are not at high risk for the flu would probably take the drug as soon as a pandemic hit anyway.

“‘Regulatory approval, of course, is the last hurdle before this world-changing technology comes to market,’ he writes. ‘Even that hurdle could be bypassed by going to a contract manufacturer if the next pandemic hits before the company is ready to manufacture on a mass scale.

“‘I hear angels singing again,’ Patrick concludes, ‘accompanied by the sound of cash register bells.’”

Best to all!